FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1523-1524 October 6, 2005 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Winton, T. PubMed Citation

To the Editor: In the randomized trial of adjuvant chemotherapy for patients with stage IB or stage II non–small-cell lung cancer reported by Winton et al. (June 23 issue),¹ a statistically significant survival advantage was found overall, but no difference was observed in the subgroup of patients with stage IB cancer. Whereas a consensus emerges from several trials about the improvement in survival in stage II disease,^2,3 controversy remains about the role of platinum-based adjuvant chemotherapy in patients with stage IB non–small-cell lung cancer.^1,2,4 We performed a literature-based meta-analysis to explore this issue. In a population of 2353 patients (seven . . . [Full Text of this Article]

This article has been cited by other articles:

• Kane, R. C. (2008). The Clinical Significance of Statistical Significance. The Oncologist 13: 1129-1133 [Abstract] [Full Text]